Clinical trials: Scleroderma
PHTN in Scleroderma Patients
Pulmonary Hypertension Screening in Scleroderma
Screening for pulmonary hypertension in scleroderma patients
- Trial name
- NCT07186439
- Volunteers
- 35 people
- Sponsor
- Assiut University
Fibrosis Lung, Systemic Sclerosis
Identifying Unique Pathogenic Macrophages in Systemic Sclerosis-ILD
Alveolar macrophages isolated from bronchoalveolar lavage (BAL) fluid from systemic sclerosis (SSc) patients with clinically significant lung fibrosis will be studied at baseline and at 6 months after enrollment to assess…
- Trial name
- NCT03438032
- Testing
- Bronchoscopy with lavage
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Scleroderma, Digital Ulcers
Riociguat in Scleroderma Associated Digital Ulcers
The primary objective of this study is to provide preliminary data on the efficacy (digital ulcer net burden) and safety of riociguat administered 3 times daily (TID) in comparison to placebo in patients with…
- Trial name
- RESCUE (NCT02915835)
- Testing
- Riociguat
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Dinesh Khanna, MD, MS
Scleroderma, Systemic, Sclerosis, Systemic
Pragmatic Clinical Trials in Scleroderma
Systemic Sclerosis (SSc) is an autoimmune connective tissue disease characterized by autoantibodies, fibrosis and microvascular injury and endothelial cell activation that results in vascular damage.
- Trial name
- PCTS (NCT03610217)
- Testing
- Interstitial lung disease induction algorithm, Pulmonary arterial hypertension algorithm, Raynaud's phenomenon algorithm
- Where
- Canada
- Volunteers
- 400 people
- Sponsor
- University of West London
Systemic Sclerosis
89Zr-Oxine-RY_SW01 Cell Injection for the Treatment of Systemic Sclerosis
Systemic sclerosis (SSc) tends to progress to involve multiple vital organs within 5 years of diagnosis, significantly impacting patient prognosis and survival.
- Trial name
- NCT06489652
- Testing
- 89Zr-Oxine-RY_SW01 Cell Injection
- Volunteers
- 8 people
- Sponsor
- Jiangsu Renocell Biotech Company
Systematic Sclerosis, Digital Ulcer
Bosentan Treatment of Digital Ulcers Related to Systemic Sclerosis
GRegistry is a significant collection of data and information on the clinical practice of systemic scleroderma finger ulcers. The GRegistry study is a nationwide (Greece) prospective study recording, which includes consecutive…
- Conditions
- Systematic Sclerosis, Digital Ulcer, Scleroderma
- Trial name
- GRegistry SCDU (NCT02798055)
- Testing
- Bosentan group
- Where
- Greece
- Volunteers
- 148 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Diffuse Cutaneous Systemic Sclerosis
A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis
The study hypothesis is that SC abatacept is safe and shows evidence of efficacy (improvement in modified Rodnan score [mRSS]) in patients with diffuse cutaneous systemic sclerosis (dcScc) compared to matching placebo.
- Trial name
- ASSET (NCT02161406)
- Testing
- Abatacept
- Where
- 27 sites in United States, Canada and 1 more
- Volunteers
- 88 people
- Sponsor
- Dinesh Khanna, MD, MS
Understand Pathogenicity of SSc-specific Antibodies in SSc and the Effect of Antibody Blockade in Vitro
AUTOANTIBODIES AND SYSTEMIC SCLEROSIS
Established in vitro assays, combined with state-of-the-art multi-omics approaches and innovative in vitro experimental models, will gain insights into the mechanistic bases underlying Systemic Sclerosis (SS) pathogenesis and…
- Trial name
- AUTO (NCT06502678)
- Testing
- Fcr blocker of autoantibodies
- Volunteers
- 6 people
- Sponsor
- IRCCS Ospedale San Raffaele
Scleroderma
Effectiveness and Safety of Lidocaine for Scleroderma
Scleroderma, or systemic sclerosis, is a chronic connective tissue disease generally classified as one of the autoimmune rheumatic diseases.
- Trial name
- NCT00740285
- Testing
- Lidocaine 2% without vessel constrictor
- Where
- Brazil
- Volunteers
- 26 people
- Sponsor
- Federal University of São Paulo
Scleroderma
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
This is a two part study. The purpose of Part A is to determine if BMS-986020 is effective in treatment of diffuse cutaneous systemic sclerosis using one dose of BMS-986020.
- Trial name
- NCT02588625
- Testing
- BMS-986020
- Where
- 27 sites in United States, Canada and 2 more
- Sponsor
- Bristol-Myers Squibb
Systemic Sclerosis
Safety Of Fat Micrografts With Adipose-Derived Stromal Vascular Fraction In Hands Of Patients With Systemic Sclerosis
Systemic sclerosis (SS) causes microvascular alteration in the hand and subsequently pain, skin fibrosis, and osteoarticular deformities.
- Trial name
- NCT04387825
- Testing
- ADSVF application in the right hand
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Systemic Sclerosis
A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis
This study was the extension of the double-blind study GLPG1690-CL-204 (NCT03798366). The main purpose of the study was to see how GLPG1690 was tolerated in participants with systemic sclerosis and whether there were any side…
- Trial name
- NCT03976648
- Testing
- GLPG1690
- Where
- 14 sites in United States, Belgium and 3 more
- Volunteers
- 31 people
- Sponsor
- Lakefront Biotherapeutics NV
Systemic Sclerosis, Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension in Systemic Sclerosis
The purpose of this study is to evaluate the role of stress echocardiography, compared to standard echocardiography in the early identification of pulmonary arterial hypertension in systemic sclerosis.
- Trial name
- NCT00617487
- Where
- 2 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Scleroderma, Systemic Sclerosis
SPIN Self-Management Feasibility Trial
The Scleroderma Patient-centered Intervention Network (SPIN) is an organization established by researchers, health care providers, and people living with scleroderma (systemic sclerosis; SSc) from Canada, the United States…
- Trial name
- SPIN-SELF-F (NCT03914781)
- Testing
- SPIN-SELF Program
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Lady Davis Institute
Systemic Sclerosis, Vulvovaginal Signs and Symptoms
Effects of Fractional CO2 Laser Treatment on Vaginal Symptoms and Sexual Dysfunction in Women With Systemic Sclerosis
Women affected by Systemic Sclerosis and Vulvovaginal Atrophy will be submitted to a cycle composed of five vaginal CO2 laser treatment (SmartXide2 V2LR, Monalisa Touch, DEKA, Florence, Italy - Hi Scan V2LR con sonda vaginale a…
- Conditions
- Systemic Sclerosis, Vulvovaginal Signs and Symptoms, Sexual Function Disturbances
- Trial name
- SCLERDERMCO2 (NCT06231433)
- Testing
- CO2 Vaginal Laser
- Where
- Italy
- Volunteers
- 16 people
- Sponsor
- IRCCS San Raffaele
Chronic Obstructive Pulmonary Disease (COPD), Smoking
Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies
The purpose of this study is to obtain biologic materials from the blood, airways and/or urine of normal individuals and individuals with lung disease.
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD), Smoking, Smoking Cessation, Idiopathic Pulmonary Fibrosis (IPF)
- Trial name
- NCT01776398
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Systemic Sclerosis, Diffuse
Iguratimod in Systemic Sclerosis
The purpose of this study is to evaluate the safety, tolerability and efficacy of iguratimod in adult subjects with diffuse cutaneous systemic sclerosis.
- Trial name
- NCT04515706
- Testing
- Iguratimod
- Volunteers
- 20 people
- Sponsor
- RenJi Hospital
Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma
A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon
The purpose of this research study is to test the safety, tolerability, and effectiveness of Topical AmphiMatrix with Nitroglycerin (MQX0503) to relieve Raynaud's symptoms and increase blood flow to the fingers.
- Conditions
- Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma, Raynaud's Disease Secondary to Other Autoimmune Disease
- Trial name
- NCT00577304
- Testing
- Nitroglycerin, Topical AmphiMatrix
- Where
- 17 sites in United States
- Volunteers
- 200 people
- Sponsor
- MediQuest Therapeutics
Healthy Volunteers, Systemic Sclerosis (SSc)
A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis.
A two-part study of PRO-203 administered subcutaneously in healthy adult volunteers and participants with Systemic Sclerosis (SSc).
- Conditions
- Healthy Volunteers, Systemic Sclerosis (SSc), Scleroderma, Systemic, Scleroderma
- Trial name
- NCT07641634
- Testing
- PRO-203
- Where
- 13 sites in Australia, China and 2 more
- Volunteers
- 44 people
- Sponsor
- Prolium Bioscience, Inc
Juvenile Systemic Sclerosis
Juvenile Systemic Sclerosis, a Retrospective Epidemiological Study on a French Cohort
Scleroderma is an inflammatory attack of the vessels leading to localized or multisystemic sclerosis. It is a rare autoimmune pathology in pediatrics.
- Trial name
- JSSc (NCT06019234)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Strasbourg, France